News | April 06, 2026
Samsung Biologics lands first US manufacturing facility with GSK acquisition
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
The plant is expected to enhance regional supply capabilities
Indoco received the Establishment Inspection Report from the USFDA for its API manufacturing facility
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
The new site enables end-to-end production of viral vector gene therapies
Subscribe To Our Newsletter & Stay Updated
